Stealth BioTherapeutics Current Ratio 2018-2021 | MITO

Stealth BioTherapeutics current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Stealth BioTherapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.03B $0.01B 2.36
2021-03-31 $0.03B $0.02B 2.10
2020-12-31 $0.04B $0.02B 1.67
2020-09-30 $0.02B $0.02B 1.07
2020-06-30 $0.03B $0.02B 1.49
2020-03-31 $0.03B $0.03B 1.07
2019-12-31 $0.05B $0.03B 1.54
2019-09-30 $0.04B $0.03B 1.40
2019-06-30 $0.06B $0.03B 2.13
2019-03-31 $0.07B $0.03B 2.72
2018-12-31 $0.01B $0.04B 0.33
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.01B $0.03B 0.24
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.066B $0.021B
Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company's product pipeline includes Elamipretide, SBT-20 and SBT-272 which are in clinical stage. Stealth BioTherapeutics Corp is based in Newton, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86